| Display title | Chemistry:SoRI-20041 |
| Default sort key | SoRI-20041 |
| Page length (in bytes) | 3,634 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 247327 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>CodeMe |
| Date of page creation | 10:30, 6 March 2023 |
| Latest editor | imported>CodeMe |
| Date of latest edit | 10:30, 6 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | SoRI-20041 is an "antagonist-like" allosteric modulator of amphetamine-induced dopamine release (in contrast to the related research chemicals SoRI-9804 and SoRI-20040, which are "agonist-like"). SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release... |
